Psychiatry and Clinical Psychopharmacology
ORIGINAL ARTICLE

The utility of psychotropic drugs on patients with Fetal Alcohol Spectrum Disorder (FASD): a systematic review

1.

Department of Psychiatry, College of Medicine, Royal University Hospital, Saskatoon, Canada

2.

Department of Academic Family Medicine, University of Saskatchewan, Saskatoon, Canada

3.

Department of Psychiatry, Faculty of Medicine, UBC, Vancouver, BC, Canada

4.

Brockville Mental Health Centre (BMHC), Brockville, Canada

5.

Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, BC Children’s Hospital, UBC, Vancouver, Canada

Psychiatry and Clinical Psychopharmacology 2018; 28: 436-445
DOI: 10.1080/24750573.2018.1458429
Read: 403 Downloads: 244 Published: 10 February 2021

BACKGROUND: Treatment of the complications arising from Prenatal Alcohol Exposure (PAE) has largely been focused on psychosocial and environmental approaches. Research on the use of medications, especially psychotropic medications, has lagged behind.

OBJECTIVES: This systematic review sought to investigate psychotropic medication related findings and outcomes in those diagnosed with Fetal Alcohol Spectrum Disorder (FASD).

METHODS: Comprehensive searches were conducted in seven major databases (Medline/ PubMed, Scopus, Web of Knowledge, Embase, PsycINFO, Cochrane Library, and PsycARTICLES) up to February 2017. Key search terms with synonyms were mapped on these databases. There were no timeline restrictions and no grey literature searches. Two reviewers independently assessed 25 studies that met the inclusion criteria. Most studies were reviews of treatment and retrospective case series.

RESULTS: Two crossover randomized trials were reported, and the findings were not amenable to meta-analysis. Several conditions (depression, agitation, seizures, and outburst) combined with the most frequent presentation, ADHD, to represent the rationale for prescribing psychotropic medications. Second-generation antipsychotics were found to improve social skills, but the paucity of data limited the extent of clinical guidance necessary for the field.

CONCLUSIONS: The systematic review showed that there are some clinical evidence displaying the validity of psychopharmacological interventions in people with FASD, which varies across the spectrum of disease severity, age, and gender. There is a need for more clinical evidencebased studies in addition to clinical expert opinions to substantiate an optimal ground for individualized management of FASD. The study protocol for this review was registered in PROSPERO with registration number CRD42016045703.

Files
EISSN 2475-0581